Skip over navigation

Open Public Meeting

The Part B Open Public Meetings (formerly known as Open Draft Meeting) are scheduled by the Noridian Contractor Medical Director(s) to allow the general public to submit information for Noridian's consideration in Medicare Local Coverage Determination (LCD) development; however, specific claims are not discussed during these meetings.

Presenters / Speakers

If you wish to make a presentation at this open meeting, contact Christine Burnside, Assistant to the Contractor Medical Directors, using the contact information provided below.

Due to time constraints, all presentations will be limited to ten (10) minutes, with an additional five (5) to ten (10) minutes allowed for discussion. Requests to present at the meeting and all final presentations must be submitted two (2) weeks prior to the event date. No changes to the presentation will be accepted after the two week deadline. Note: Presentations will be sent to registrants prior to the meeting date. Visual equipment will not be available at the meeting site to project presentations.


There are two ways to participate:

  1. In person (at host site location)
  2. Teleconference

To attend in person, you must pre-register with Christine Burnside no later than two weeks prior to event date. Directions for those choosing to attend in person will be provided by Noridian upon receipt of registration request. Only those registered will be able to attend this meeting due to capacity limits.

State(s) Date Time Location Teleconference Topics for Agenda
All 02/08/2017 1 - 2 p.m. CT Noridian Healthcare Solutions
Room N3
900 42nd Street S
Fargo, ND 58108-6704
Access Number: 405-874-844
  • Cataract Surgery in Adults
  • Coenzyme Q10 (CoQ10)
  • MolDX: Comprehensive Genomic Profiling to Guide Treatment in Patients with Advanced Primary Peritoneal, Fallopian Tube and Ovarian Cancer
  • MolDX: Comprehensive Genomic Profiling to Guide Treatment in Patients with Metastatic Colorectal Cancer
  • MolDX: Comprehensive Genomic Profiling to Guide Treatment in Patients with Metastatic Melanoma
  • MolDX: DecisionDx-UM (Uveal Melanoma)
  • 4Kscore Assay
  • MolDX: Prolaris™ Prostate Cancer Genomic Assay for Men with Favorable Intermediate Risk Disease
  • MolDX: VectraDA, a Multibiomarker Disease Activity Test for Rheumatoid Arthritis (RA)
  • MolDX: Vita Risk™ Pharmacogenetic Test for Dry Agerelated Macular Degeneration (AMD)
  • MolDX: Xpresys Lung
  • Plastic Surgery
  • Repetitive Transcranial Magnetic Stimulation (rTMS) in Adults with Treatment Resistant Major Depressive Disorder
  • Visual Electrophysiology Testing


LCDs are administrative and educational tools that assist providers, physicians and suppliers in submitting correct Medicare claims for coverage. Draft LCDs are accessible from the Noridian Draft LCDs webpage.

Send all written comments for Part B regarding the draft policies by mail or email to:

Mail Email
Noridian JF Part B CMD Policy Development
900 42nd Street S
P.O. Box 6704
Fargo, ND 58108-6704


Last Updated Feb 01, 2017